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Retinoic acid receptors (RARs) are ligand-dependent
transcription factors that control a plethora of physi-
ological processes. RARs exert their functions by
regulating gene networks controlling cell growth,
differentiation, survival, and death. Uncovering the
molecular details by which synthetic ligands direct
specificity and functionality of nuclear receptors is
key to rational drug development. Here we define
the molecular basis for (E)-4-[2-[5,6-Dihydro-5,5-
dimethyl-8-(2-phenylethynyl)naphthalen-2-yl]ethen-
1-yl]benzoic acid (BMS204,493) acting as the inverse
pan-RAR agonist and define 4-[5,6-Dihydro-5,5-di-
methyl-8-(quinolin-3-yl)naphthalen-2-carboxamido]
benzoic acid (BMS195,614) as the neutral RARa-
selective antagonist. We reveal the details of the
differential coregulator interactions imposed on the
receptor by the ligands and show that the anchoring
of H12 is fundamentally distinct in the presence of
the two ligands, thus accounting for the observed
effects on coactivator and corepressor interactions.
These ligands will facilitate studies on the role of
the constitutive activity of RARs, particularly of the
tumor suppressor RARb, whose specific functions
relative to other RARs have remained elusive.
INTRODUCTION
Three retinoic acid receptors (RARa [NR1B1], RARb [NR1B2], and
RARg [NR1B3]) mediate biological processes regulated by reti-
noids (Chambon, 1996; Germain et al., 2006; Mark et al., 2006).
Mechanistic studies of RARs and other members of the nuclear
receptor (NR) superfamily have demonstrated that ligand binding
modulates the ability of the receptor to ‘‘communicate’’ with its
intracellular environment, which entails essentially receptor-
protein and receptor-DNA/chromatin interactions. Upon binding,Chemistry & Biology 16a ligand allosterically alters receptor surfaces required for interac-
tion with coactivator (CoA) and corepressor (CoR) complexes
that are central to the control of target gene transcription. RAR
agonists facilitate the exchange between CoR and CoA
complexes by destabilizing CoR and stabilizing CoA-RAR inter-
faces. The subsequent recruitment of epigenetically active and/or
chromatin-modifying complexes leads to chromatin alterations
that facilitate activation of target gene expression by the basal
transcriptional machinery. In the absence of agonists, RARs
can actively repress gene transcription as nonliganded RAR
establishes CoR complexes comprising repressive factors, which
are believed to promote chromatin compaction (for recent
reviews see Gronemeyer et al., 2004; Lonard and O’Malley,
2007; Rosenfeld et al., 2006). The physiological impact of CoRs
in NR signaling has been recently revealed by gene deletion
studies (Astapova et al., 2008; Nofsinger et al., 2008).
This active transcriptional silencing mediated by RARa in
complex with its retinoid X receptor (RXR) heterodimeric partner
is a direct consequence of their association with CoRs such as
silencing mediator for retinoid and thyroid hormone receptors
(SMRT)/T3 receptor-associating cofactor (Chen and Evans,
1995; Jepsen et al., 2007; Sande and Privalsky, 1996) or nuclear
receptor corepressor (NcoR)/receptor interacting protein 13
(Horlein et al., 1995; Seol et al., 1996; Zamir et al., 1996). These
cofactors exhibit modular structures facilitating the assembly of
high molecular weight complexes and serve also as CoRs for
other nuclear orphan receptors (Zamir et al., 1996) and transcrip-
tion factors (see, for example, Evert et al., 2006; Melnick et al.,
2002). Among others, Sin3A and histone deacetylases are factors
found in these complexes (Alland et al., 1997; Heinzel et al., 1997;
Nagy et al., 1997). The formation of a CoR complex with associ-
ated histone deacetylase activity at the promoters of NR target
genes is believed to cause transcriptional silencing through
histone deacetylation and chromatin condensation at receptor-
targeted loci. Binding of an agonist to RAR induces a conforma-
tional switch of the ligand-binding domain (LBD), leading to the
release of CoRs and concomitant association of CoA complexes.
Our understanding of how ligand binding leads to the activa-
tion of NRs has been greatly advanced by structural studies of, 479–489, May 29, 2009 ª2009 Elsevier Ltd All rights reserved 479
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peptides (Bourguet et al., 2000b). Together with biochemical
analyses, these studies demonstrated that the activation func-
tion 2 in helix 12 (AF-2 H12) of the LBD is critically involved in
NR activation. Indeed, in the case of RARs, agonistic ligands
establish a direct contact to H12 residues and maintain the helix
in a position that generates a surface with increased affinity for
the LxxLL motifs (also called NR box), which are located in the
NR-interacting surface of CoA proteins. In all reported cases,
the LxxLL peptide forms a short a helix, which is bound to the
hydrophobic groove generated by the carboxy-terminal part of
H3, the loop L3-4, and H4 of the LBD.
Correlative analyses of biochemical data and sequences
provided evidence that CoA and CoR recruitment share a similar
molecular basis. Evaluating CoR binding to mutants in the CoA
binding site of the thyroid hormone receptor a (TRa, NR1A1)
demonstrated that mutations that impair activation and CoA
recruitment also decrease repression and CoR binding, thus
indicating that NCoR binds to a NR surface topologically related
to that involved in CoA interaction (Hu and Lazar, 1999). Mapping
of the NR determinants of NCoR binding using a series of muta-
tions introduced in TRa indicated that the groove formed by resi-
dues from helices H3 and H4 corresponds to the primary CoR
binding site but that H11 and H12 are not involved.
The C-terminal NR-interacting region of SMRT and NCoR is
composed of two or three independent interacting subdomains
(IDs) (Cohen et al., 2001; Seol et al., 1996; Zamir et al., 1996).
Examination of the two interaction domains ID1 and ID2 in
SMRT and NCoR revealed sequences (CoRNR1 and CoRNR2
by analogy to NR boxes of CoAs; note that the numbering of
CoRNR1 to CoRNR2 is from N to C terminus and that the ID1/2
and CoRNR1/2 nomenclature is used synonymously) similar but
not identical to the LxxLL motif of CoAs, which were also pre-
dicted to adopt an amphipathic helical conformation (Hu and
Lazar, 1999; Nagy et al., 1999; Perissi et al., 1999). Chimeric
CoRNR box peptides were designed to show that although the
consensus hydrophobic core FxxFF is necessary and sufficient
for CoR binding, sequences flanking the CoRNR box strengthen
the interaction and determine NR specificity. In addition, within
CoR, the two CoRNR boxes are not equivalent. CoRNR box 1
interacts almost exclusively with RAR/TR and CoRNR box 2 binds
to both heterodimeric partners. Perissi et al. (1999) further
extended the analogy to the helical CoA LxxLL motifs. They
proposed a model in which the CoRNR box motif would fold in
a significantly longer LxxI/HIxxxI/L helix when compared to the
CoA LxxLL NR box motif. This model is supported by the crystal
structure of a ternary complex containing the PPARa-LBD bound
to the SMRT CoRNR2 motif (Xu et al., 2002). In the absence of
agonists, the CoRNR box helix could interact with the H3-H4
hydrophobic groove displayed by unliganded receptors. How-
ever, in the presence of an agonist, the repositioning of the activa-
tion helix H12 in its active (holo) conformation would prevent this
interaction. Indeed, in contrast to the unliganded NR case, the
length of the helix that can be accommodated by the H12-con-
taining groove is strictly defined by the presence of the charge
clamp that specifically recognizes helices of the NR box type
(Nolte et al., 1998). Together, these results showed that, unex-
pectedly, CoAs and CoRs use similar mechanisms of interaction
with distinct NR conformations. Discrimination by NR H12 helix of480 Chemistry & Biology 16, 479–489, May 29, 2009 ª2009 Elsevierthe lengthsof CoA and CoR interaction helices occupyingpartially
overlapping binding sites may constitute the molecular basis of
ligand-mediated coregulator exchange on NRs.
Retinoids and rexinoids (RXR-selective ligands) have significant
promise for the treatment and prevention of cancer and other
diseases (Altucci and Gronemeyer,2001; Altucci et al., 2007; Shul-
man and Mangelsdorf, 2005). As the natural ligand all-trans reti-
noic acid (atRA) acts as pan-RAR agonist and 9-cis retinoic acid
activates both RARs and RXRs, synthetic medicinal chemistry
efforts have been directed to the generation of RXR and RAR
subtype-selective ligands with the goal to improve therapeutic
indices by eliminating adverse effects possibly caused by acti-
vating/repressing the action of other receptor subtypes. Conse-
quently, manysynthetic retinoids have beengenerated that exhibit
a distinct pattern of agonistic/antagonistic activities with the three
RARs (for reviews see Dawson, 2004; de Lera et al., 2007).
Here we report on the comparative mechanistic analysis of
two distinct types of retinoid antagonists, BMS204,493 and
BMS195,614 (hereafter referred to as BMS493 and BMS614; for
chemical structures see Figure 1A). We define BMS493 as inverse
agonist because it strongly enhances NCoR interaction by selec-
tively stabilizing the ID1/CoRNR1 interface and destabilizing ID2/
CoRNR2 association in the context of the RAR-RXR heterodimer.
In a striking contrast, BMS614 acts as a neutral antagonist, as it
does not significantly affect NCoR binding and moderately
decreases SMRT binding to RAR; importantly, it does not support
CoA interaction but rather antagonizes agonist-induced CoA
recruitment. Probing the ligand-induced conformational changes
revealed that the anchoring of H12 is fundamentally distinct in the
presence of BMS493 and BMS614, thus accounting for the diver-
gent effects on CoA and CoR interaction. This study illustrates
the potential of NR-based drug design and reveals that subtle
changes in the chemical structure of the ligand translate in very
selective effects on the communication potential of the receptor
with the promise of a drug-directed fine tuning of the cognate
signaling pathways.
RESULTS
Inverse Agonists Modulate CoR Binding to RAR
Transient transactivation-based ligand competition assays
derived from challenging 10 nM TTNPB pan-RAR agonist with
an increasing concentration of BMS493 revealed that BMS493
is a powerful pan-RAR antagonist (Figure 1B). Two-hybrid anal-
yses performed in Cos cells with chimeras containing the GAL4
DNA binding domain fused to the NCoR or SMRT (termed Gal-
NCoR and Gal-SMRT) and the LBD of either RARa, b, or g fused
to the activation domain of VP16 (termed RAR-VP16) showed not
only that RAR-CoR interaction was maintained in the presence of
BMS493 but, moreover, that NCoR interaction was strongly
(NCoR; Figure 1C) or moderately (SMRT; Figure 1D) enhanced
in the presence of BMS493 (see figure legend for a more detailed
explanation of the two-hybrid results). Due to this reinforcement
of CoR interaction with RARs, we reasoned that BMS493 should
increase the repression function of all three RARs in intact cells.
Indeed, BMS493 efficiently decreased the basal level of a retinoic
acid-responsive chimeric gene (RARE3-tk-Luc) in transient trans-
fections with all three RARs in HeLa cells (Figure 2A). Moreover, in
the same cell line, BMS493 decreased both the expression ofLtd All rights reserved
Chemistry & Biology
RAR Inverse Agonists and Neutral Antagonistsendogenous CYP26 (Figure 2B), a RAR target gene known to
harbor a retinoic acid response element in its promoter, and the
chromatin acetylation status of the CYP26 promoter in vivo
(Figure 2C). Thus, BMS493 is a bona fide pan-RAR inverse
agonist.
Figure 1. RAR Antagonist Potential of
BMS493
(A) Chemical structures of RAR ligands.
(B) To assess antagonistic activities of BMS493,
HeLa cells were cotransfected with reporter (17
m)5x-G-Luc and Gal-RARa (closed squares),
Gal-RARb (open triangles), or Gal-RARg (closed
circles). The reporter was activated by 10 nM
TTNPB (100%) and increasing concentrations of
BMS493 were added, as indicated.
(C and D) Mammalian two-hybrid assays with
(17 m)5x-G-Luc and Gal-NCoR (C) or Gal-SMRT
(D) as bait and VP16-RARs as prey were performed
in HeLa cells to assess the influence of indicated
synthetic retinoids at 1 mM on interaction between
all three RARs and both CoRs NCoR and SMRT in
a cellular context. 100% corresponds to reporter
gene transcription induced in the absence of ligand
(RAR apo forms). In the two-hybrid assays, a
chimeric luciferase-based reporter gene ((17 m)
5x-G-Luc) is transfected together with two expres-
sion vectors. One expresses a fusion protein (Gal-
NCoR or Gal-SMRT) that binds through the Gal
DNA binding domain (Gal) to the pentamer of the
‘‘17m’’ DNA recognition site in the reporter gene
and contains the C-terminal region of the CoR,
which can interact with RARs. Note that this region
does not recruit HDAC repressor complexes. The
other vector expresses a second fusion protein
composed of the VP16 acidic transcription activa-
tion domain, a domain that confers constitutive
transcription activation if it is brought close to
a promoter and the LBD of RAR. If a ligand induces
RAR-CoR interaction this results in (indirect)
recruitment of the VP16 acidic transcription activa-
tion domain to the promoter of the luciferase
reporter gene, thereby inducing transcription and
luciferase protein production that is quantitated in
the luminometer.
Transient transactivation studies with
all three RARs revealed that two other
synthetic retinoids, AGN192,870 and
AGN193,109 (hereafter referred to as
AGN870 and AGN109; for chemical struc-
tures see Figure 1A), displayed divergent
receptor-selective activity (Figure 2A).
While AGN870 is a weak agonist for
RARa and b, it acts as a weak inverse
agonist for RARg, in keeping with its ability
to stabilize NCoR binding to RARg, which
is significantly higher than to RARa or
b (Figure 1C). Notably, SMRT binding was
rather decreased in the presence of
AGN870; this effect was most pronounced
for RARb (Figure 1D). This demonstrates
that AGN870 modulates RAR activity in a
receptor subtype and CoR-selective manner and that the acquired
pattern of coregulator interaction apparently accounts for its
activity as a RARa/b agonist and (weak) RARg inverse agonist.
Contrary to AGN870, AGN109 is a weak inverse agonist for
RARa and b (Figure 2A), which is apparently due to its greaterChemistry & Biology 16, 479–489, May 29, 2009 ª2009 Elsevier Ltd All rights reserved 481
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on SMRT binding was seen for RARa and b, but the interaction of
both SMRT and NCoR with RARg was strongly stimulated by
AGN109 (Figures 1C and 1D). Relative to BMS493, the effect
of AGN109 on the interaction with RARg was more pronounced
for NCoR than for SMRT. Consequently, AGN109 is another
inverse pan-agonist with a particular RARg-selective effect on
NCoR recruitment. Together the above results demonstrate
that synthetic retinoids can be designed that modulate RAR-
CoR interaction in a RAR subtype and CoR-selective fashion.
BMS493 Stabilizes NCoR-RAR Binding by Targeting
CoRNR Box 1
To assess whether one or more of the three receptor IDs of
NCoR mediate the enhancing effect of BMS493, we studied
its effects on the interaction of the previously defined CoRNR
box peptides 1 and 2 (CoRNR1 and CoRNR2) (Hu and Lazar,
1999) with the RARa LBD by electrospray ionization mass spec-
trometry (ESI-MS) under nondenaturing conditions. Note that
we have not observed any significant interaction of ID3 with
RARs or RAR-RXR heterodimers (see below). In the absence
of ligand, ESI-MS revealed two approximately equally abundant
populations of molecules that correspond to the RARaLBD and
the RARaLBD-CoRNR1 complex (Figure 3A, top). Addition of
BMS493 resulted in the disappearance of these species and
the appearance of a single novel peak with a mass correspond-
ing to the RARaLBD-BMS493-CoRNR1 complex (Figure 3A,
bottom). No such effect was observed with the CoRNR2 peptide
even though both the LBD and the LBD-CoRNR2 complex effi-
ciently bound BMS493, as is obvious from mass shift of these
A
C
B Figure 2. RAR Inverse Agonist Potential of
BMS493-Inducing Transcriptional Repres-
sion in HeLa Cells
(A) HeLa cells were cotransfected with the reporter
(RARE)3x-tk-Luc and RARa, b, or g in the presence
of the indicated synthetic retinoids at 1 mM or in the
absence of ligands (100%, basal transcriptional
activity).
(B) Kinetics of CYP26 expression investigated by
semiquantitative RT-PCR performed with primers
specific for retinoic acid-responsive CYP26 or
GAPDH (used as control) mRNAs using total RNA
of HeLa cells either treated with atRA or BMS493
at 1 mM, as indicated.
(C) ChIP assays using antibodies directed against
acetylated histones H4 and HeLa cells treated with
either atRA or BMS493 at 1 mM for 30 or 60 min.
Immunoprecipitated chromatin was analyzed by
PCR using primers specific for CYP26 or L32
(used as control) promoters. NA, ChIP assays
were performed using no antibody.
species, which corresponds to the added
mass of the retinoid (Figure 3B).
We then addressed whether the
features of BMS493 were affected by het-
erodimerization. By using mass spectrom-
etry we studied the binding efficiencies
of the synthetic peptides encompassing
CoRNR1 and CoRNR2 in the context of the purified RXRa LBD-
RARaLBD heterodimer. In the absence of ligand, equal amounts
of heterodimers bound either CoRNR1 or CoRNR2 (45% and
40%, respectively; Figures 3C and 3D, top panels; note that the
peptides were added in molar excess over the heterodimer).
Both peptides dissociated quantitatively in the presence of the
RAR agonist Am80 (Figures 3C and 3D, bottom panels). No tetra-
meric RAR-RXR-CoRNR1-CoRNR2 complex was observed in
experiments where the two peptides were added simultaneously
(data not shown). As with RAR monomer, the inverse agonist
BMS493 strongly stabilized the interaction between the hetero-
dimer and CoRNR1 (Figure 3C, middle panel). However, in
a striking contrast to the RAR monomer results, the hetero-
dimer-CoRNR2 complex was significantly destabilized upon
binding of this inverse agonist (Figure 3D, middle panel), such
that the most abundant species (R80%) is the RXR-RAR/
BMS493-CoRNR1 complex. Therefore, other than in the case of
the RAR monomer (see above), the BMS493-bound heterodimer
does not apparently contain a binding surface that is accessible
for CoRNR2 of NCoR.
Two-hybrid analyses with the previously reported chimeras,
which encompass the Gal4 DNA binding domain and one of the
three NCoR IDs (Gal-ID1, Gal-ID2, and Gal-ID3), fully supported
the above in vitro results (Figure 4A). Gal-ID1 interaction with
VP16-RARa was strongly stimulated by BMS493, whereas no
ligand effect was seen with Gal-ID2. No significant interaction
was seen with Gal-ID3. Mutations were introduced in both
NCoR ID1 and ID2 to test the contribution of each ID in the context
of the NCoR containing both IDs. Importantly, NCoR harboring
a mutated ID1 or a mutated ID2 behaved like ID2 alone or ID1482 Chemistry & Biology 16, 479–489, May 29, 2009 ª2009 Elsevier Ltd All rights reserved
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demonstrate that the BMS493-enforced NCoR interaction with
RARa is mediated specifically by ID1.
This conclusion was further supported by investigating NCoR
interaction with the two other RARs. Two-hybrid assays with
RARb, which binds CoRs less efficiently than RARa, and NCoR
ID mutants revealed that BMS493 strongly increased the interac-
tion between NCoR and RARb in an ID1 integrity-dependent
manner (Figure 4C). Similar conclusions were made for RARg
(data not shown). Note that the weaker RARb interaction with
NCoR is apparently due to a weaker interaction of ID1 with RARb
relative to RARa. Overall our results demonstrate that BMS493-
enhanced RAR-NCoR binding is due to a selective effect of the
ligand on the interaction of the receptors with CoRNR1/ID1 and
a destabilization of the CoRNR2/ID2 interaction seen for the
RAR monomer.
Mechanism of Action of the Neutral Antagonist BMS614
Characterization of the molecular actions of other RAR antago-
nists, such as BMS614, led to the definition of ‘‘neutral retinoid
antagonists’’ as compounds that destabilize CoR complexes but
do not induce recruitment of CoAs. Two-hybrid analyses with
chimeras composed of the Gal4 DNA binding domain and the
NR ID of the CoA TIF2 (referred to as Gal-TIF2.5; this fusion protein
harbors all three LxxLL NR boxes of TIF2) showed that Gal-TIF2.5
Figure 3. BMS493 Stabilizes NCoR CoRNR1
Peptide Binding to RARa
(A) Positive ESI mass spectra of RARaLBD-
CoRNR1 complexes in the absence of ligand
(top) or in the presence of 2-fold molar excess of
BMS493 (bottom).
(B) Positive ESI mass spectra of RARaLBD-
CoRNR2 complexes in the absence of ligand
(top) or in the presence of 2-fold molar excess of
BMS493 (bottom).
(C and D) Positive ESI mass spectra of RXRaLBD-
RARaLBD-CoRNR1 complexes in the absence of
ligand (top) or in the presence of 2-fold molar
excess of BMS493 (middle) or Am80 (bottom), or
RXRaLBD-RARaLBD-CoRNR2 complexes in the
absence of ligand (top) or in the presence of 2-
fold molar excess of BMS493 (middle) or Am80
(bottom). Note that the illustrations indicate the
existence of a quaternary BMS493/RAR/RXR/
CoRNR complex but are not meant to specify
interface(s) of the CoRNR peptides with the heter-
odimer. Peaks labeled with an asterisk correspond
to species with an additional N-terminal methio-
nine. Please note that the numbering of CoRNR1
to CoRNR2 is from N to C terminus.
interaction with VP16-RARa was strongly
stimulated by the agonist Am80, while
no significant interaction was seen with
BMS614 or BMS493; both antagonists
efficiently counteracted Am80-induced
interaction (Figure 5A). Fluorescence
anisotropy experiments with a fluores-
cein-labeled NR box 2 peptide of SRC-1
fully supported the two-hybrid results
(Table 1). In keeping with its agonistic activity, Am80 binding
to RARa LBD monomer strongly enhanced the binding affinity
of SRC-1 NR box 2 more than 17-fold (apparent Kd values are
0.47 mM and 8.18 mM for the Am80-RARa and apo-RARa
LBDs, respectively). The BMS493-RARa LBD displayed a similar
affinity for SRC-1 NR box 2 as the apo-RARa LBD, while
BMS614 even reduced the affinity of RARa by 11-fold (apparent
Kd = 92.70 mM).
Two-hybrid analyses in Cos cells showed not only that RAR-
CoR interaction was enforced in the presence of BMS493 but,
moreover, that BMS493 was able to induce CoR interaction
even with the so-called RARa ‘‘AHT’’ mutant (RARAHT harbors
the mutations A194G, H195A, and T198A in helix H1) (Horlein
et al., 1995; Schulman et al., 1997), which was reported to be
deficient for CoR binding (Figure 5B) (Vivat et al., 1997). Indeed,
very weak binding was seen with apo-RARAHT but BMS493 is
apparently able to restore CoR binding to an extent similar to
that seen with wild-type apo-RAR. In a striking contrast,
BMS614 is unable to induce such an effect. In the presence of
this ligand, SMRT interaction with wild-type RAR was signifi-
cantly decreased, while NCoR interaction was similar to that of
apo-RAR. Moreover, BMS614 could not overcome the effect of
the ‘‘AHT’’ CoR box mutation, indicating that this ligand is unable
to generate a surface compensating for the effect of the AHT
mutation. The SMRT interaction pattern was recapitulated byChemistry & Biology 16, 479–489, May 29, 2009 ª2009 Elsevier Ltd All rights reserved 483
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C484 Chemistry & Biology 16, 479–489, May 29, 2009 ª2009 Elsevfluorescence anisotropy analyses with a peptide (CoRNR1)
derived from SMRT ID1 (Table 1). The dissociation of the
SMRT CoRNR1-apoRARa LBD complex (Kd = 0.20 mM) strongly
increased upon Am80 binding (Kd = 3.80 mM) and was slightly
reduced (Kd = 0.18 mM) by BMS493. Importantly, the association
of BMS614 to the RARa LBD provoked a robust reduction of
SMRT-CoRNR1 binding affinity (Kd = 2.88 mM), similar to values
obtained for the agonist Am80. Overall our results demonstrate
that based on their mechanism of action the two antagonists
BMS493 and BMS614 have to be classified as inverse agonist
and neutral antagonist, respectively.
Crucial Role of H12 Positioning in Inverse Agonist
and Neutral Antagonist Action
It is well known that ligand binding induces a conformational
change in NRs. Protease digestion studies can not only reveal
such changes but also distinguish between distinct structural
alterations induced by agonists and antagonists. We therefore
examined the molecular basis of ligand-induced structural
changes in RARa by limited proteolysis studies. Carboxypepti-
dase Y (CY) is a vacuolar serine carboxypeptidase from Saccha-
romyces cerevesiae, which catalyzes a stepwise removal of
C-terminal amino acids from proteins. This exopeptidase has
been used previously to reveal altered positioning by protease
sensitivity of the C-terminal H12 of RARs in the presence of
a particular ligand (Lin et al., 1997). Indeed, apo-RARawas highly
sensitive to CY digestion, indicating that H12 is accessible to the
enzyme, while TTNPB (agonist) or BMS614 (neutral antagonist)
binding conferred resistance to CY (Figure 5C, top panel, lanes
5–7 and 11–13). These results are consistent with, and can be
readily explained from, previously reported 3D LBD structures
for agonist and BMS614-bound RARa (compare Figure 5D,
left). In these structures, H12 is tightly packed against the body
of the LBD in the presence of an agonist and embedded in
a hydrophobic groove formed by H3 and H4 in the presence of
BMS614; such structures are compatible with a poor suscepti-
bility to CY attack. In a striking contrast to BMS614, the inverse
agonist BMS493 did not confer any detectable resistance of
RARa toward CY exopeptidase attack, as the proteolysis pattern
of unliganded and BMS493-bound RARa were virtually indistin-
guishable (Figure 5C, top panel, compare lanes 2–4 and 8–10).
This indicates that H12 is less tightly bound to the body of the
LBD and thus more susceptible to proteolysis. Importantly,
however, this difference is only seen with the exopeptidase.
Indeed, there is a very similar protection of the LBD against endo-
peptidase attack when RAR is bound to BMS493, BMS614, or
TTNPB, as revealed by virtually identical protection patterns
seen with trypsin (Figure 5C). Thus, the three above ligands
Figure 4. BMS493 Increases NCoR Interaction with RARs Specifi-
cally through ID1
Mammalian two-hybrid assays with (17 m)5x-G-Luc reporter were performed
in HeLa cells as in Figure 1.
(A) Transient transfections with VP16-RARa and Gal-ID1, Gal-ID2, or Gal-ID3.
(B and C) Transient transfections with VP16-RARa (B) or VP16-RARb (C) and
Gal-NCoR harboring both IDs (ID1 + ID2), mutations in ID1 (ID1m + ID2), or
mutations in ID2 (ID1 + ID2m). In all assays, both TTNPB and BMS493 are
used at 0.1 mM and 1 mM, respectively. Please note that the numbering of
CoRNR1 to CoRNR2 is from N to C terminus.ier Ltd All rights reserved
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LBD core as revealed by acquired resistance to trypsin but
BMS493 differs from BMS614 and TTNPB in that it does not
induce a tight packing of H12.
To gain additional direct insight into this differential packing of
H12 we introduced mutations (RARV240R in H3 and RARI258R in
H4; see Figure 5D) into RARa that correspond to those previously
reported to impair both CoA and CoR interaction for TR and RXR
(Hu and Lazar, 1999). These mutations disrupt the H3/H4 hydro-
phobic groove to which the CoR FxxFF and CoA LxxLL motifs
bind. Interestingly, neither of the mutations alters the CY protec-
tion pattern for RARa complexes with TTNPB or BMS493
(compare for each mutant the EtOH mock treatment with the
ligand treatment in Figure 5C, middle and bottom panels, lanes
A B
C
D
Figure 5. BMS493 and BMS614 Represent
Two Different RARa Antagonist Classes
(A) Mammalian two-hybrid assays with (17 m)5x-
G-Luc reporter were performed in HeLa cells as in
Figure 1. Transient transfections with VP16-RARa
and Gal-TF2.5 harboring the nuclear ID of TIF2.
(B) Transient transfections with Gal-NCoR, Gal-
SMRT and VP16-RARa (VP16-RAR), or VP16-
RARaAHT mutant (VP16-RARAHT). Only BMS493
is able to rescue VP16-RARAHT mutant for interac-
tion with CoRs. Both BMS493 and BMS614 are
used at 1 mM.
(C) Ligands differently alter protease sensitivity of
RARa. Partial proteolysis maps of in vitro-trans-
lated RARs in the presence or absence either
of TTNPB, BMS493, or BMS614. Radiolabeled
RARs were exposed to CY for 10, 30, or 60 min as
indicated. Top, wild-type RARa; middle, RARa
V240R mutant; bottom, RARa I258R mutant. (right)
Wild-type RARa, RARa V240R mutant, or RARa
I258R mutant were exposed to trypsin for 10 min.
(D) Model of the structural basis of ligand action.
(left) Schematic drawing of two different conforma-
tional states of RAR LBDs elucidated from crystal
structures. Superposition of the LBDs of the
agonist-bound (holo) atRA RARg (orange) and the
RARa-BMS614 complex (blue). Agonist ligands
induce a conformation in which the holo position
of H12 is stabilized. This active conformation
provides a surface to which CoAs can bind via their
NR boxes that contain LxxLL motifs. In contrast,
BMS614 binding allows H12 to bind to the static
part of the hydrophobic groove and then blocks
by competition both CoA and CoR binding. (right)
The crystal structure of the PPARaLBD (green) in
a complex with the antagonist GW6471 and the
CoRNR2 motif (red) of SMRT reveals that the
binding of GW6471 to PPARa prevents the proper
positioning of H12 in its agonistic site (Xu et al.,
2002). H12 is stabilized in an alternative position
that may generate an optimal interaction surface
for CoRs.
2–10). In contrast, on complexation with
BMS614, both mutants exhibited a signifi-
cantly increased sensitivity toward CY
(lanes 11–13). This result supports a
model in which residues V240 and I258 are
required for tight interaction of H12 with the LBD core in the pres-
ence of BMS614. Importantly, none of the mutations altered the
resistance of RARa to trypsin degradation, as identical proteo-
lytic maps were observed for wild-type and mutant RARa
irrespective of the bound ligand (Figure 5C).
DISCUSSION
In the present study, we report on the very different mechanistic
and structural bases for the antagonism exerted by two retinoids,
which we classify as neutral antagonist (BMS614) and inverse
agonist (BMS493) due to the very different coregulator interaction
patterns that these ligands impose onto RARs. Apart from the
mechanistic insight in how subtle changes in the structure ofChemistry & Biology 16, 479–489, May 29, 2009 ª2009 Elsevier Ltd All rights reserved 485
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receptor, which is discussed below, these compounds are also
novel tools in understanding complex signaling pathways
through pharmacological ‘‘dissection’’ with ligands that induce
a defined subset of activities. It is, for example, unclear why
RARb exerts features of tumor suppressor (see Introduction for
references), which is not the case for RARa or g. One difference
between the RARs is the rather high ligand-independent activity
of RARb. Compounds like BMS493, optimally subtype specific,
allow us to decrease the constitutive activity of a RAR to study
its loss-of-function consequences in suitable systems.
Our data suggest that BMS493 binding induces analogous
conformational change in all three RARs, indicating that the posi-
tioning of BMS493 within the ligand-binding cavities is similar.
This is apparently not the case for other previously described
inverse agonists. Indeed, the mammalian two-hybrid assays
reported here reveal that AGN109, which was originally described
as inverse agonist (Klein et al., 1996), is generally less efficient
than BMS493 at inducing the recruitment of CoRs and exerts
convincing inverse agonist effects only on RARg.
This suggests a weaker overall repression potential of AGN109,
possibly due to a positioning of AGN109 in the ligand-binding
cavity, which generates a suboptimal CoR-binding interface.
Conversely, AGN870 is a weak transcriptional activator capable
of preventing CoR association with RARa and RARb. As
AGN870 differs from AGN109 only by the absence of a methyl
group, these results reveal that relatively subtle ligand modifica-
tions can significantly alter the conformation of the LBD and
H12 positioning, thereby generating distinct coregulator binding
interfaces. Considering the divergent CoR interaction patterns
induced by these compounds, they may possibly act in a cell
type-selective manner. In contrast, BMS493 is expected to act
as a strong global silencer of RAR-dependent gene activation
programs. Cell type-specific ligand activities have indeed been
reported for the class of so-called ‘‘selective oestrogen receptor
modulators’’ (for a review, see Gronemeyer et al., 2004). In the
case of selective oestrogen receptor modulators the tissue selec-
tive response is thought to be the consequence of differences
in cell/tissue-specific coregulator levels. Similarly, the partial
activity of RU486 with the progesterone receptor has been linked
to differential CoR and CoA expression (Liu et al., 2002). Together
our observations demonstrate that it is possible to generate RAR
ligands with very selective profiles, in terms of coregulator binding
interfaces generated and RAR-coregulator complexes formed,
which can finally result in very different transcriptional outcomes.
Table 1. Binding Affinities of Coregulator Peptides for RARa LBD
Dissociation Constants (mM)
Ligands Fluo-SRC-1 NR2 Rho-SMRT CoRNR1
No ligand (apo) 8.18 ± 0.30 0.20 ± 0.02
Am80 0.47 ± 0.02 3.80 ± 0.41
BMS493 12.70 ± 0.80 0.18 ± 0.01
BMS614 92.70 ± 20.00 2.88 ± 0.35
Dissociation constants of SRC1 NR2 or SMRT CoRNR1 peptides from
purified monomeric RARa LBD were determined using the fluorescein-
labeled NR box 2 peptide of the CoA SRC-1 or the rhodamine-labeled
CoRNR1 peptide of the CoR SMRT, respectively.486 Chemistry & Biology 16, 479–489, May 29, 2009 ª2009 ElsevierA general feature common to all antagonists crystallized to
date is the presence of a bulky side chain that cannot be accom-
modated within the agonist binding cavity. In our previous work
we reported that in the RARaLBD-BMS614 complex (Bourguet
et al., 2000c) the antagonistic quinolyl group of BMS614 points
toward H12 and exits the binding pocket between H3 and H11.
In contrast to RAR agonists, which stabilize the active conforma-
tion of holo-H12, thereby promoting CoA recruitment (as in the
RARbLBD-9-cis-RA-LxxLL complex; Pogenberg et al., 2005),
this particular position of BMS614 prevents the positioning of
H12 in the active conformation. Furthermore, the RARaLBD-
BMS614 structure reveals that H12 binds and occludes the
CoA binding site by mimicking the hydrophobic interactions
of the LxxLL motif of CoAs. This suggests that BMS614 may
prevent interaction of CoA by inducing H12 stabilization in the
hydrophobic cleft formed by H3, H4, and the H3/H4 loop, with
the consequence that H12 competes with CoA binding. The
reported fluorescence anisotropy and two-hybrid data support
this view, as RARa interacts very poorly (even weaker than unli-
ganded RARa) with CoAs upon BMS614 binding. Additional
arguments in favor of a model in which H12 binds to the CoA
interaction surface in the BMS614-RARa complex are provided
by limited proteolysis study with exopeptidase CY. Overall, our
study reveals that BMS614 acts as a pure RARa AF2 antagonist
that prevents CoA binding most likely by stabilizing H12 in the
hydrophobic cleft.
From a structural point of view, the crystal structure of a ternary
complex comprising the PPARa-LBD, the antagonist GW6471,
and a SMRT CoR motif (Xu et al., 2002) supports the model in
which CoA and CoR binding sites are largely overlapping
(Figure 5D, right). Conceptually, H12, CoA, and CoR could
compete with each other for the hydrophobic groove of RARa,
which is formed by H3, H4, and the loop LH3-H4. According to
such a concept, BMS614 would reduce the affinities of both
CoA and CoR for RARa, as is demonstrated by the fluorescence
anisotropy experiments, due to H12 stabilization in this groove.
While all these studies have been very revealing, the question of
what determines BMS493-mediated CoR interaction to RARs
remains open. Obviously the differential recruitment of CoRs in
the presence of BMS493 and BMS614 has to be a consequence
of the allosteric effects on RARa. The induction of a stable posi-
tioning of H12by the agonistorBMS614directs the transcriptional
readout from RARa by (1) enhancing (agonist) or reducing
(BMS614) the affinity toward theLxxLLmotif ofCoAsand (2)simul-
taneous destabilization of CoR binding. Conversely, BMS493,
which functions also as RAR antagonist, strongly stabilizes CoR
interaction, with ID1 being both necessary and sufficient to fortify
NCoR association. Therefore, helix H12 has to adopt in the
BMS493-RARa complex an alternative position that favors CoR
association specifically through ID1. As for BMS614, the antago-
nistic activitymediated byBMS493 has to beexerted through allo-
steric effects. Both BMS493 and BMS614 side chain substitutions
are too long to be accommodated within the ligand-binding cavity
and instead exit the pocket, interfere with H12 alignment, and
thereby generate AF2 antagonism. Interestingly, our limited prote-
olysis assays imply an instability of the H12 conformation upon
BMS493 binding, which is in stark contrast to H12 stabilization
by BMS614; obviously a confirmation of this hypothesis has to
await the establishment of a BMS493/RARaLBD/CoR structure.Ltd All rights reserved
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coregulators by inducing H12 stabilization in the hydrophobic
groove with H12 acting as competitor precluding coregulator
interaction, while BMS493 may bind to RAR such that it physically
prevents H12 from adopting either its characteristic agonist
(TTNPB) or AF2 antagonist (BMS614) orientation and thereby
abrogates the interaction between H12 and the core of the LBD
entirely. In this respect, BMS493 resembles the antiestrogen
ICI164384. Indeed the crystal structure of the ERbLBD-
ICI164384 complex revealed that, in contrast to other ER antago-
nists, H12 cannot adopt a defined position (Pike et al., 2001). The
binding of this compound to ERb completely abolishes the asso-
ciation between H12 and the remainder of the LBD. However, it
cannot be excluded that the extensiveflexible antagonistic substi-
tution of ICI164384 interferes directly with coregulator binding;
this is unlikely to occur in the case of BMS493, which has a very
rigid structure and allows CoR recruitment. We note, however,
that in the crystal structure of the GW6471-PPARa-LBD-CoRNR2
complex H12 is loosely packed against H3, leaving sufficient
space to accommodate the CoR motif (Xu et al., 2002). Thus,
under the influence of a ligand, H12 can be stabilized, albeit
poorly, in a position that is different to the well characterized
holo and AF2 antagonistic conformations (see Figure 5D, right).
Overall our results suggest that the positioning of the BMS493
phenyl moiety and interference with H12 positioning are crucial
features that generate RAR inverse agonism.
Reversible histone acetylation, governed dynamically by
histone acetyl transferases and deacetylases, plays a pivotal
role in regulation of gene expression through remodeling chro-
matin structure; histone deacetylation being associated with
transcriptional repression of genes. The fact that the pan-RAR
inverse agonist stabilizes the association of RARs with CoRs
in vitro raises the possibility that it could be used not only to block
the effect of agonistic retinoid signals but also to silence the
constitutive expression levels of retinoid-responsive promoter.
Indeed, BMS493 exposure reduced the luciferase levels seen
in the absence of ligand from a RARE-luciferase transgene
and, more importantly, also the basal expression level of the
endogenous CYP26 gene, which is known to harbor a functional
RARE. Notably, BMS493 treatment also reduced basal histone
acetylation of theCYP26 promoter. Given that BMS493 enforces
CoR binding to cognate promoters and that CoRs assemble
complexes that contain histone deacetylases, we conclude
that BMS493 stabilizes the entire CoR complex at RAR target
sites in vivo, suggesting that chromatin histone deacetylation is
(part of) the mechanism by which inverse agonists inhibit basal
target gene transcription.
SIGNIFICANCE
A major goal of drug development for an identified pharma-
ceutical target is the generation of modulators that display
increased target selectivity and/or functional specificity in
order to reduce potential side effects. The 48 members of
the NR family that possess bona fide LBDs are attractive
drug target because (1) they are master regulators of a large
variety of major (patho)physiological processes and (2) their
cognate ligands are small molecules that are convenient for
chemical synthesis. Importantly, subtle changes in theChemistry & Biology 16structure of a cognate ligand can direct the activity toward
a particular receptor subtype and various types of functional
specifications, such as agonism/antagonism, (hetero)dimer
selectivity, or cell/pathway selectivity like the one underlying
the concept of NR modulators. In the present study we
describe the molecular basis of two very distinct types of
ligands, an inverse agonist (BMS204,493) and a neutral
antagonist (BMS195,614) for the RAR family. We show that
a differential interaction with coregulators is the basis of
the different functionality of these two ligands. As the core-
gulators are platforms for complexes with epigenetic activ-
ities, such as histone methyl/acetyltransferases and deace-
tylases, such ligands can be used to regulate RAR-mediated
gene programs in very different directions. We have previ-
ously shown that RARb, which is generally considered
a tumor suppressor, is unique in that it displays constitutive
activity for transactivation and transrepression. The avail-
ability of ligands that are able to act as inverse agonists
like BMS204,493 allows us to investigate the role of the
constitutive activity of RARb and may illuminate its function
as a tumor suppressor.
EXPERIMENTAL PROCEDURES
Materials and Chemicals
The histidine-tagged LBD of human RARa1 (residues176–421 in pET15b
vector) and the LBD of mouse RXRa1 (residues 227–467 in pET3a vector)
were expressed in Escherichia coli BL21(DE3). Purification of the RXRaLBD-
RARaLBD heterodimer was performed as described previously (Bourguet
et al., 2000a). Peptides containing CoRNR1/ID1 and CoRNR2/ID2 sequences
(Hu and Lazar, 1999) were synthesized and used as model peptides for the
CoR proteins. CoRNR1/ID1 is a 24 amino acid peptide (THRLITLADHIC
QIITQDFARNQV; 2806 Da) containing the consensus sequence that specifi-
cally interacts with the RAR subunit. CoRNR2/ID2 contains 14 amino acids
(NLGLEDIIRKALM; 1541 Da). GAL-TIF2.5, Gal-NCoR (contains NCoR from
1629 to the C terminus), and Gal-SMRT (contains SMRT from 982 to the
C terminus), as well as Gal-NCoR derivatives harboring both IDs (ID1 and
ID2), mutations in ID1 (ID1m and ID2), or mutations in ID2 (ID1 and ID2m),
have been described (Germain et al., 2002; Hu and Lazar, 1999; Voegel
et al., 1998). The pSG5-based Gal-RARa and VP16-RARa expression vectors
and the (17 m)5x-G-Luc reporter gene have been described previously (Nagpal
et al., 1993). (RARE)3-tk-Luc is a gift from P. Balaguer and has been described
previously (Germain et al., 2004). Am80 was a generous gift of K. Shudo;
BMS195,614 (Vivat et al., 1997) and BMS204,493 (Germain et al., 2002)
were provided by Bristol-Myers Squibb; and AGN192,870 and AGN193,109
were provided by Galderma. TTNPB and atRA were purchased from Sigma.
Cell Culture and Transient Transfections
HeLa cells, cultured in Dulbecco’s modified Eagle’s medium/5% fetal calf
serum, were transfected by using the standard calcium phosphate method
as previously described (Vivat et al., 1997). Results were normalized to coex-
pressed b-galactosidase.
Chromatin Immunoprecipitation and RT-PCR
ChIP assays were carried out with the acetyl-histone H4 immunoprecipitation
assay kit (Upstate Biotechnology). Briefly, approximately 106 HeLa cells were
treated with ligands for 2 hr and ChIP assays were done using antisera against
acetyl histone H4 as specified by the manufacturer. PCR of the CYP26 gene
promoter was performed with ChIP using the following oligonucleotides:
CYP26 forward, 50-GCGGAACAAACGGTTAAAG; CYP26 reverse, 50-CCAG
AGCTTGATCGCAG; L32 forward, 50-CCGTAGCTGGCGATTGGAAGAC; L32
reverse, 50-TTGACATATCGGTGTGACTGGTG. For RT-PCR, the following
oligonucleotides were used: cyp26 forward, 50- CGCGAGGCACTCGAATGC
TACGTG; cyp26 reverse, 50- CGCGTGAATGAGGTTCCGCGCCTT; GAPDH, 479–489, May 29, 2009 ª2009 Elsevier Ltd All rights reserved 487
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GTTGAGGGCAATGCCAGCC.
ESI-MS Analysis
Prior to any ESI-MS analysis, samples were desalted on Centricon PM30 micro-
concentrators (Amicon, Millipore) in 100 mM ammonium acetate (pH 6.5).
Ammonium acetate presents the advantage not only to preserve the ternary
and quaternary structures of proteins in solution but also to be compatible
with ESI-MS experiments.
ESI-MS measurements were performed on an electrospray time-of-flight
mass spectrometer (LCT, Waters). Purity and homogeneity of the retinoid
receptors were verified by mass spectrometry analysis in denaturing condi-
tions: proteins were diluted to 5 pmol/ml in a 1:1 water-acetonitrile mixture
(v/v) acidified with 1% of formic acid. Mass spectra were recorded in the posi-
tive ion mode on the mass range 500–2500 m/z, after calibration with horse
heart myoglobine diluted to 2 pmol/ml in a 1:1 water-acetonitrile mixture (v/v)
acidified with 1% of formic acid. The following molecular weights were
measured: 29,930 ± 1.8 Da for RARa and 26,735 ± 2.3 Da for RXRa with dele-
tion of the N-terminal methionine and 26,867 ± 2.1 Da corresponding to RXRa.
These results were in agreement with the molecular weights calculated from
the known amino acid sequences.
The mass measurements of the noncovalent complexes were performed in
ammonium acetate (50 mM; pH 6.5). Samples were diluted to 10 pmol/ml in the
previous buffer and continuously infused into the ESI ion source at a flow rate
of 6 ml/min through a Harvard syringe pump. Great care was exercised so that
noncovalent interactions survive the ionization/desorption process. Especially
the accelerating voltage (Vc), which controls the kinetic energy communicated
to the ions in the interface region of the mass spectrometer, was optimized to
50 V in order to prevent ligand dissociation in the gas phase. ESI-MS data were
acquired in the positive ion mode on the mass range 1000–5000 m/z. Calibra-
tion of the instrument was performed by using the multiply charged ions
produced by a separate injection of horse heart myoglobine diluted to
2 pmol/ml in a 1:1 water-acetonitrile mixture (v/v) acidified with 1% of formic
acid. The relative abundance of the different species present on ESI mass
spectra were measured from their respective peak intensities, assuming that
relative intensities displayed by the different species on the ESI mass spec-
trum reflect the actual distribution of these species in solution. The reproduc-
ibility of the determination of the relative proportions of the different species
was estimated to be ±2%–3%.
Fluorescence Anisotropy Assays
Steady-state fluorescence anisotropy assays were performed with a BEACON
2000 polarization instrument (Panvera) regulated at 4C as described previ-
ously (Pogenberg et al., 2005). Fluorescent peptides (fluorescein-RHKILHRLL
QEGS corresponding to the NR box 2-binding motif of SRC-1 and rhodamine-
RVVTLAQHISEVITQDYTR corresponding to the CoRNR1-binding motif of
SMRT) were purchased from Neosystem.
Limited Proteolytic Digestion
In vitro-made 35S-radiolabelled RARs (TNT kit, Promega) were used. Briefly,
for trypsin, after incubating on ice for 1 hr, ligand receptor proteins were
digested at 25C for 10 min with 100 mg/ml trypsin as described previously
(Germain et al., 2004). For CY, each time point contained 1 ml of TNT reaction
products and 7 ml of 50 mM Tris-HCl (pH 6.8) and either 10 mM of ligand or an
equivalent amount of ethanol carrier. After incubating on ice for 1 hr, ligand
receptor proteins were digested at 25C for either 10, 30, or 60 min with 2 ml
CY (1 mg/ml; Sigma).
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